1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Costco reported fourth-quarter fiscal 2026 net sales of $93.9 billion, up 11.2%, and net income of $3.00 billion, or $6.75 per diluted share, compared with $5.87 a year earlier. The quarter included a non-recurring benefit of $0.15 per diluted share from IEEPA tariff refunds, partly reinvested in member values, so shareholders see both stronger headline results and a one-time boost.
Q4 net sales rose 11.2% to $93.9 billion; Q4 total company comparable sales were up 9.4%, or 6.7% excluding gasoline prices and foreign exchange.
Q4 diluted EPS was $6.75 versus $5.87; the quarter included a $0.15 per diluted share non-recurring tariff refund benefit.
Fiscal 2026 net income was $9.226 billion, or $20.76 per diluted share, versus $8.099 billion, or $18.21, in fiscal 2025.
Fiscal 2026 net sales rose 10.1% to $297.2 billion; the company operates 939 warehouses.
Infleqtion announced that it entangled 30 logical qubits using 80 physical qubits on its Sqale quantum computing platform, a milestone on its 2026 roadmap. The filing contains no financial results or guidance, so the announcement's direct effect on shareholders is limited to the company's stated technology progress and roadmap targets.
Demonstration of 30 entangled logical qubits using 80 physical qubits on the Sqale platform, announced September 24, 2026
Company targets 100 logical qubits in 2028 and 1,000 logical qubits by 2030
Infleqtion says it has three customers for logical qubit circuits on the Sqale platform, including the Wellcome Leap Q4Bio program
H.B. Fuller reported third-quarter 2026 results for the quarter ended August 29, 2026, with net revenue of $938 million, up 5.2% year-on-year, and diluted EPS of $1.44 against $1.22 a year earlier. The company also updated its fiscal 2026 guidance, now expecting adjusted EBITDA of $655 million to $670 million and adjusted diluted EPS of $4.70 to $4.85, citing year-to-date performance.
Net revenue was $938 million, up 5.2%; organic revenue rose 4.4%, with pricing adding 7.4% and volume lower.
Adjusted EBITDA was $187 million, up 9%, and adjusted EBITDA margin was a record 19.9%, up 80 basis points.
Net income was $79 million versus $67 million a year earlier; net working capital rose to 18.5% of annualized net revenue.
Updated fiscal 2026 guidance: adjusted EBITDA of $655 million to $670 million and adjusted diluted EPS of $4.70 to $4.85; the filing does not state the prior ranges.
Sky Quarry Inc. said it received an air permit from the Nevada Division of Environmental Protection and restarted operations at its Eagle Springs Refinery near Ely, Nevada, on September 24, 2026. The company completed about $300,000 in repairs and upgrades before the restart, and the filing states no financial results for the refinery. The restart is an operational step, but the filing gives no revenue, profit or sales figures, so shareholders cannot yet judge its financial effect.
Nevada Division of Environmental Protection issued an air permit for the Eagle Springs Refinery.
About $300,000 in repairs and upgrades were completed, based on a TAR360 assessment commissioned in 2025.
Stated nameplate capacity is about 5,000 barrels of crude oil per day, with about 15,000 barrels of crude oil inventory on hand.
BlackBerry reported results for the quarter ended August 31, 2026, with revenue up 26% year-over-year to $163.3 million and GAAP net income of $33.9 million, compared with $13.3 million a year earlier. The company also raised its fiscal 2027 revenue and adjusted EBITDA outlook, which gives shareholders updated guidance for the year ending February 28, 2027.
Revenue was $163.3 million, up 26% year-over-year; QNX revenue was $80.3 million, a record quarter for the segment.
GAAP net income was $33.9 million, positive for the sixth consecutive quarter; adjusted basic EPS was $0.07.
Fiscal 2027 total revenue guidance is $616 million to $636 million, and total adjusted EBITDA guidance is $141 million to $158 million.
Third-quarter fiscal 2027 revenue guidance is $143 million to $154 million, ending November 30, 2026.
Darden reported first-quarter fiscal 2027 sales of $3.2 billion, up 5.1%, with blended same-restaurant sales up 3.1% on a fiscal calendar basis. Diluted EPS from continuing operations was $2.05, up 4.1% from prior-year adjusted EPS of $1.97, though below the $2.19 reported a year earlier, which included a one-time gain on the Olive Garden Canada sale. The company reaffirmed its fiscal 2027 EPS outlook of $11.10 to $11.35 and declared a $1.62 quarterly dividend.
Total sales rose 5.1% to $3.2 billion; LongHorn Steakhouse same-restaurant sales rose 6.2% on a fiscal calendar basis.
Diluted EPS from continuing operations was $2.05, up 4.1% from prior-year adjusted EPS of $1.97; reported prior-year EPS was $2.19.
Darden repurchased $222.3 million of stock and has $1.3 billion remaining under its $1.5 billion authorization.
Quarterly dividend of $1.62 per share is payable November 2, 2026, to holders of record on October 9, 2026.
TD SYNNEX reported fiscal third-quarter 2026 results for the period ended August 31, 2026, with revenue of $21.6 billion, up 37.7% from a year earlier, and GAAP diluted EPS of $5.18 versus $2.74. The company also declared a quarterly dividend of $0.48 per share payable October 30, 2026, and gave fourth-quarter revenue guidance of $21.8 billion to $22.6 billion with non-GAAP diluted EPS of $5.65 to $6.15.
Q3 revenue was $21.6 billion, up 37.7% year over year, and above the high end of the company's outlook
GAAP net income was $416 million versus $227 million a year earlier; GAAP operating margin was 2.98% versus 2.45%
Q4 fiscal 2026 guidance: revenue of $21.8 billion to $22.6 billion and non-GAAP diluted EPS of $5.65 to $6.15
Quarterly dividend of $0.48 per share, up 9% year over year, payable October 30, 2026 to holders of record on October 16, 2026
Kyverna Therapeutics said one-year topline data from its KYSA-8 registrational trial in stiff person syndrome (SPS) and longer-term Phase 2 follow-up data from KYSA-6 in generalized myasthenia gravis (gMG) were positive. The company said it remains on track to complete its rolling BLA submission in Q4 2026, and the filing contains no financial results, guidance, or deal terms.
KYSA-8: median timed 25-Foot Walk improvement of 49% at month 12 among 26 SPS patients (p < 0.0001)
KYSA-6 Phase 2: all 7 gMG patients reached clinically meaningful improvement at 24 weeks; 57% maintained minimal symptom expression at last follow-up
Rolling BLA submission for miv-cel in SPS is on track for completion in Q4 2026; full data at MS Toronto, October 21-23, 2026
Conference call set for 8:00 a.m. Eastern Time on September 24, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.